The evaluation of the survival and toxicité with cisplatinum and taxol regimen in stage IV ovarian carcinoma

Objective: We aimed to assess the effects of the combination of cisplatin + paclitaxel (taxol) in patients with epithelial ovarian cancers
Material and Method: 13 patients with stage IV epithelial ovarian cancer who followed up more than 6 months in our clinic were evaluated retrospectively.
Result: The avarage age is was 54 (29-72). For their age groups; 7.6% of patients in 21-30, 30.7% of patients in 41- 50, 23% of patients 51-64 and 38. 4% of patients in 65+ age groups. All of the patients were with stage IV (FIGO). Serum Cal2-5 level was high in 61.5% of patients. Debulking surgery was performed 11 of patients. All of the patients were received chemotherapy regimens which involved cisplatinum (75 mg/m2) and paclitaxel (175 mg/m2), D1, every 21 days, total of 6. cycles. None of patients had haematologic and non- haematologic toxicities. Median survival was 14.6 months and 2-years sürvival was 23 months.
Conclusion: The combination of Cisplatinum and Taxol which, is the standart treatment of ovarian carcinoma is effec¬tive and less toxic regimen. The age of patient and the stage of disease are the most important prognostic factors.

Evre IV epitelyal over kanserli hastalarda cisplatin-taxol kombinasyonu ile toksisite ve saðkalým deðerlendirilmesi

Amaç: Over Ca’h hastalarda Cisplatin + Paclitaxel (Taxol) kombinasyonu He elde edilen sonuölann retrospektif deðerlendirilmesi amaçlandý.
Materyal ve Metod: Kliniðimize evre iv epitelyal over kanseri tanýsý ile müracaat eden ve takipleri 6 aydan uzun olan 13 hasta, uygulanan tedavi ve sonuçlarý yönünden retrospektif olarak deðerlendirilmiþtir.
Bulgular: Hastalarýn yaþ gruplarýna göre daðýlýmlarý: 1 has¬ta (%7.6) 21-30 yaþ grubu, 4 hasta(%30.7) 41-50 yaþ grubunda, 3 hasta (%23) 51-64 yaþ grubunda, 5 hasta (%38.4) 65 ve üzeri yaþ grubundadýr. Hastalarýn median yaþý 54 (29- 72) dür Hastalarýn tamamý baþvuru sýrasýnda evre IV (FIGO) olarak deðerlendirildi. Tümör markerlerinden serum CA 12-5 düzeyi 8 hastada (%61.5) yüksek, 3 hastada bakýlmamýþ ve 2 hastada normal olarak bulundu. Hastalarýn IV e debulking amaçlý operasyon yapýlmýþ, 2 has¬ta sadece biopsi ile over Ca olarak kabul edilmiþtir. Hastalara adjuvan olarak cisplatin(75 mg/m2) + Taxol (175 mgtm.2) DÝ 21 günde bir olmak koþulu ile toplam 6 kür uygulanmýþtýr. Hastalarýn 8’ inde kemoterapi uygulamasý süresince hafif hipersensitivite reaksiyonu görülmüþ olup, grade (WHO) 3-4 hematolojik ve non-hematolojjk toksisiteye rastlanmamýþtýr. Medyan saðkalým 14.6 ay, 2 yýllýk ortalama saðkalým %23 olarak belirlendi.
Sonuç: Over kanserinin standart tedavisi olarak kabul edilen cisplatin-taxol kombinasyonun etkili ve toksisitesi düþük bir rejim olduðu, bunun yaný sýra hasta yaþý ve evrenin saðkalýmý etkileyen en önemli prognostik faktörler olduðu görülmüþtür.